Investigational Product (Pharmaceutical) Management. Sudhakar Bangera MD, MMedSc Program Director, CDSA
|
|
- Rosemary Harrison
- 5 years ago
- Views:
Transcription
1 Investigational Product (Pharmaceutical) Management Sudhakar Bangera MD, MMedSc Program Director, CDSA
2 Investigational Product Definition (CDSCO GCP) - A pharmaceutical product (including the Comparator Product) being tested or used as reference in a clinical study - An Investigational Product may be an active chemical entity or a formulated dosage form
3 Investigational Product Definition (ICH E6) - Is a pharmaceutical form: of an active ingredient or placebo being tested or used as a reference in a clinical trial including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form or when used for unapproved indication, or when used to gain further information about an approved use
4 Investigator Brochure Chemical, pharmaceutical, toxicological, pharmacological and clinical data including the available data from previous and ongoing clinical studies
5 General Considerations Physical, chemical, pharmaceutical properties and the formulation of the IP must be documented to permit appropriate safety measures to be taken during the course of a study Instructions for the storage and handling of the dosage form should be documented Any structural similarity(ies) to the other known compounds should be mentioned
6 Relevant Components of Protocol Name and description of the investigational product(s) Description of and justification for the route of administration, dosage regimen and treatment periods for IP and Comparator. Accountability procedures for the investigational products including the comparator product Subject withdrawal criteria (i.e. terminating IP)
7 Handling of the Product Measures to be implemented to ensure the safe handling and storage of the pharmaceutical products. Label should necessarily contain the following information: the words - For Clinical Studies only, the name or a code number of the study, name and contact numbers of the investigator, name of the institution, subject s identification code
8 Data Handling and Management Procedures for handling and processing records of effects and adverse events to the product(s) under study
9 Sponsor Responsibilities Responsible for supplying the Investigational Product s, including Comparator(s) and Placebo, if applicable Products should be manufactured in accordance with the principles of GMP Should be suitably packaged in the manner that will protect the product from deterioration and safeguard blinding procedures Should be affixed with appropriate investigational labeling
10 Label and Labeling Label" is the written information on the drug/device itself or its packaging Labeling" refers to this label and any descriptive or informational literature accompanying the drug/ device
11 Label Format Name of the medicinal product Randomisation/ coding number Quantitative declaration of the active substance Excipients, preservatives Method of administration Warnings Shelf-life Storage precautions & conditions
12 Label Format Special precautions Instruction For Clinical Research Use Only Batch number Name & Address of the Manufacturer
13 Labeling Font size not less than 7pts and minimum of 3mm between lines Legible Multi colored for clear distinguishing from background Printed in English and perhaps local language No long sentences If the IP is packed in a vial, the label should not be more than 3/4 th of the bottle Generic name bolder than trade name Diagrams can be used to reduce the need of the text
14 Packaging cgmp requirements for the control of drug product containers and closures 1. Drug product containers and closures shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug beyond the official or established requirements 2. Container closure systems shall provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product even while in transit
15 Packaging 3. Drug product containers and closures shall be clean and, where indicated by the nature of the drug, sterilized and processed to remove pyrogenic properties to ensure that they are suitable for their intended use 4. Documentation of test methods, methods of cleaning, sterilizing, and processing to be maintained 5. No. of units
16 Sponsor Responsibilities Should not supply an Investigator/ Institution with the Product until the Sponsor obtains all required documentation (e.g. approval/ favorable opinion from EC and Regulatory Authorities Document procedures and lay down responsibilities for: a) Adequate and safe receipt, handling, storage, reconstitution procedures and devices for product infusions, and dispensing of the Product b) Retrieval of unused Product from the Subjects and c) Return of unused Product to the Sponsor (or its alternative disposal procedure)
17 Sponsor Responsibilities Maintain records for retrieval of IP (e.g. retrieval after study completion, expired product retrieval etc.) Maintain records of the quantities of IP with proper batch numbers Ensure that the Investigator is able to establish a system within his/ her Institution for proper management of IP as per the procedures Should maintain sufficient samples from each batch and keep the record of their analyses and characteristics for reference
18 Sponsor Responsibilities The coding system for the IP should include a mechanism that permits rapid identification of the products in case of a medical emergency Patient Drug Accountability Record 2 years after marketing application is approved or discontinued
19 Shipping Tamper evident drug shipping bags Cold chain Training for Biopharmaceutical Shipping
20 Monitor Responsibilities The Monitor should verify (and wherever necessary make provisions to ensure) that a) The IP is sufficiently available throughout the study and is stored properly b) Supplied only to subjects who are eligible to receive it and at the specified dose(s) and time(s) c) Subjects are provided with the necessary instructions on proper handling of the product(s) d) Prescribed procedures for storage, handling, dispensing and return of IP are being followed and their compliance is being documented in a form as in the SOPs
21 Investigator Responsibilities Investigator has the primary responsibility for investigational product(s) accountability at the study site(s) Preferably the pharmacy department of the site should assume responsibility Responsibility to be mentioned upfront in the study agreement Maintain records of the product s delivery to the study site, the inventory at the site, the use by each subject, and the return to the sponsor or the alternative disposal of the unused product(s). These records should include dates, quantities, batch/ serial numbers, expiry dates if applicable, and the unique code number assigned to the IP packs and study subjects
22 Investigator Responsibilities Maintain records that describe that the subjects were provided the dosage specified by the protocol and reconcile all IP received from the sponsor. Ensure that the product(s) are stored under specified conditions and are used only in accordance with the approved protocol Should be thoroughly familiar with the safety, efficacy and appropriate use of the IP as described in the protocol, IB and other information sources provided by the sponsor from time to time Ensure that all persons involved in the study are adequately informed about the IP
23 Pill Reminders Mul$- Alarm Medica$on Reminder Once- A- Day Vibra$ng Pendant Reminder MeDose "Pediatric" watch
24 Drug Disposal Purpose-built, high temperature incineration with adequate flue gas cleaning Best Non-biodegradable antibiotics, antineoplastics and disinfectants should not be disposed of into the sewage system as they may kill bacteria necessary for the treatment of sewage, damage aquatic life or contaminate drinking water Burning at low temperatures or in open containers results in release of toxic pollutants into the air May allow drugs to be diverted for resale to the general public Return to Sponsor or CTM company
25 Drug Disposal Landfill: - Place waste directly into a land disposal site without prior treatment or preparation after immobilization by encapsulation or inertization - Open uncontrolled non-engineered dump Untreated wastes must be covered rapidly with large quantities of municipal waste to prevent scavenging Can lead to pollution with the risk of drinking water contamination - Engineered sanitary landfill Evacuated pit isolated from watercourses and above the water table Each day s solid waste is compacted and covered with soil to maintain sanitary conditions
26 Drug Disposal Waste immobilisation: Encapsulation - Immobilizing the pharmaceuticals in a solid block within a plastic or steel drum - Clean drum is filled to 75% capacity with solid and semisolid pharmaceuticals, and the remaining space is filled by pouring in a mixture of lime, cement/ plastic foam/ bituminous sand and water in the proportions 15:15:5 (by weight) and the drum filled to capacity - Drum sealed by spot welding - Placed at the base of a landfill and covered by municipal solid waste
27 Drug Disposal Waste immobilisation: Inertization - Removing the packaging materials, paper, cardboard and plastic from the pharmaceuticals. (Pills need to be removed from their blister packs) - The pharmaceuticals (65%) are then ground and a mix of lime (15%), cement (15%) and water (5%) added to form a homogenous paste - The paste is then transported in the liquid state by concrete mixer truck to a landfill and decanted into the normal urban waste. The paste then sets as a solid mass dispersed within the municipal solid waste
28 Drug Disposal Sewer - Syrups, antiseptics, and IV fluids, can be diluted with water and flushed into the sewers in small quantities over a period of time into a fast flowing watercourses Burning in open containers - Very small quantities of waste pharmaceuticals - Paper and cardboard packaging, if they are not to be recycled, may be burnt. Polyvinyl chloride (PVC) plastic however must not be burnt
29 Drug Disposal Medium temperature incineration - Expired solid form pharmaceuticals mixed with solid municipal waste (1:1000) - A two chamber incinerator that operates at the minimum temperature of 850 C, with a combustion retention time of at least two seconds in the second chamber *High temperature incineration using existing industrial plants (Cement kilns) - > 1200 C - For large quantities of solid and semi-solid pharmaceuticals Chemical inactivation
30 Drug Disposal SEM Disintegrators-DS 22 - Waste is fed into the unit - Falls into a destruction chamber - 5 rotating knives pass by 2 stationary bed knives - Cut the waste smaller and smaller with each pass - Final waste is determined by an interchangeable security screen - Drops out of the destruction chamber - Evacuated to a waste collection bin
31 Thank You
MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS
ANNEX 13 MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS Introduction Medicinal products intended for research and development trials are not at present subject either to marketing or manufacturing Community
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationBRIEFING 1168 Compounding for Phase I Investigational Studies,
BRIEFING 1168 Compounding for Phase I Investigational Studies, PF 39(5) [Sept. Oct. 2013]. The current proposed chapter in PF 43(3) [May June 2017] is posted online at www.usp.org/usp-nf/notices/compounding-forphase-i-investigational-studies
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationI. Purpose. II. Definitions. Last Approval Date
Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics
More informationStandard Operating Procedures
Standard Operating Procedures 5.14.1 Investigational Product Handling and Storage History Version Date Author Reason 1.1 23 rd August B Fazekas New procedure 2007 1.2 16 th October 2007 B Fazekas Update
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationMEDICINES CONTROL AGENCY. Guideline for Safe Disposal of Medicines and Related Products
MEDICINES CONTROL AGENCY Guideline for Safe Disposal of Medicines and Related Products FORWARD The Medicines Control Agency (MCA) established by an Act of Parliament and assented to on 24th December 2014
More informationGuideline on the label design for Injections (Draft for Comments)
Guideline on the label design for Injections (Draft for Comments) 2018.3 Content Foreword... 3 1. Scope... 4 2. Terms and definitions... 4 3. Basic requirements for labels... 4 4. Design principles of
More informationINVESTIGATIONAL DRUG MANAGEMENT OVERVIEW
NORTHWELL HEALTH OFFICE OF RESEARCH COMPLIANCE STUDY FEASIBILITY AND APPROVAL Where can I learn about the investigational drug? Protocol Investigator s brochure Product insert or prescribing information
More informationDrug Accountability. Kevin E. Anger PharmD, BCPS Manager Investigational Drug Services Brigham and Women s Hospital
Drug Accountability Kevin E. Anger PharmD, BCPS Manager Investigational Drug Services Brigham and Women s Hospital Session Objectives Define drug accountability and drugs in need of these accountability
More informationOFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE
OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE 1. Purpose: To describe the procedures related to the development of protocol and investigational
More informationIMP Management and Accountability
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationThe Right Prescription for Working with Investigational Drug Service at BMC
The Right Prescription for Working with Investigational Drug Service at BMC Andrew Schoch Pharmacy Intern Northeastern University Class of 2010 Hyeseon Hong, Pharm.D. IDS Pharmacy Manager What is Investigational
More informationDRUG REGULATORY PROCEDURES IN TANZANIA: A GLIMPSE
DRUG REGULATORY PROCEDURES IN TANZANIA A GLIMPSE Available online at www.ijdra.com REVIEW ARTICLE Jain Achin*, Venkatesh M P, Pramod Kumar T M. JSS College of Pharmacy, JSS University, S.S. Nagar, Mysore-570015,
More informationDate: 2 nd June 2010 Version: 3 Page 1 of 16 AND LABELLING (NWORTH 3.08) Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10
Page 1 of 16 STANDARD OPERATING PROCEDURE FOR TRIAL SUPPLIES AND LABELLING (NWORTH 3.08) Approvals Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10 Quality Assurance Officer Name: D.
More informationFormulation Development & CTM Manufacturing Services
Formulation Development & CTM Manufacturing Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides an extensive range
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationManagement and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility
Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility Document Detail Document type Standard Operating Procedure CRF-STU-SOP-1: Management and Accountability
More informationStandard Operating Procedure
Standard Operating Procedure Title: Clinical Site Monitoring Status: PRIVATE Author Name: Audrey Strader Approver Name: Christine Kubiak Document no.: CSM 02 Effective date: 11/01/2016 Review Date (if
More informationPOLICY Investigational Drug Service Transport
Investigational Drug Service Huntsman Cancer Hospital 1950 Circle of Hope, Suite 2110 Salt Lake City, Utah 84112 POLICY Investigational Drug Service Transport Purpose A. This policy establishes procedures
More informationManagement and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility
Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility Document Detail Document type Standard Operating Procedure CRF-STU-SOP-1: Management and Accountability
More informationCentral Bio-Medical Waste Treatment Facility
Central Bio-Medical Waste Treatment Facility Central Biomedical Waste Treatment Facility, Swami Ram Cancer Institute and Research Centre Campus, Government Medical College, Rampur Road, Haldwani is the
More informationBrussels, C(2017) 8179 final. Guidelines
EUROPEAN COMMISSION Brussels, 8.12.2017 C(2017) 8179 final Guidelines Detailed Commission guidelines on good manufacturing practice for investigational medicinal products for human use, pursuant to the
More informationECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies
ECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies SOP number: ECTU TM 17 Signature Date Authored by: Holly Ennis, Trial Manager 6 th Sept 2017 Reviewed by: Laura Forsyth, Trial Manager
More informationVOLUME 4 Good manufacturing practices ANNEX 13 Manufacture of investigational medicinal products JULY 2003
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, F2/BL D(2003) Revision
More informationSan Jose, California, USA
Glisland, Inc. San Jose, California, USA http://www.glisland.com Welcome to the Drug GMP World Current Good Manufacturing Practice cgmp ICH Q10 Pharmaceutical Quality System PQS GMP QSR Quality System
More informationPharmaceutical Regulatory Authority GUIDELINE ON APPLICATION FOR REGISTRATION OF UNREGISTERED VETERINARY MEDICINES ALREADY ON THE ZAMBIAN MARKET
GUIDELINE ON APPLICATION FOR REGISTRATION OF UNREGISTERED VETERINARY MEDICINES ALREADY ON THE ZAMBIAN MARKET ABBREVIATIONS µg Microgram API Active Pharmaceutical Ingredient ATC Anatomic Therapeutic Chemical
More informationEvaluation of Pharmaceutical Waste Disposal Practices in Healthcare Facilities in Lagos State, South West Nigeria
Evaluation of Pharmaceutical Waste Disposal Practices in Healthcare Facilities in Lagos State, South West Nigeria Article by Margaret Okama Obono Master of Public Health, Texila American University, Nigeria
More informationGUIDELINES ON FORMAT AND CONTENT OF LABELS FOR MEDICINAL PRODUCTS
Doc. No. TFDA/DMC/MCER/---- TANZANIA FOOD AND DRUGS AUTHORITY GUIDELINES ON FORMAT AND CONTENT OF LABELS FOR MEDICINAL PRODUCTS (Made under Section 52 (1) of the Tanzania Food, Drugs and Cosmetics Act,
More informationPHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS
RADIOPHARMACEUTICALS Guideline Title Radiopharmaceuticals Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC Date of first adoption December 1990 Date of entry into June
More informationISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual
The StAmP Trial: A Proof of Principle, double blind, Randomised Placebo-Controlled, Multi Centre Trial of Statins to Ameliorate Early Onset Pre-eclampsia. ISRCTN: 23410175 EudraCT Number: 2009-012968-13
More informationClimate change impact of waste management - A study based on Tajikistan s pharmaceutical waste management
Climate change impact of waste management - A study based on Tajikistan s pharmaceutical waste management Authors: Devni Acharya 1 Dr. Kristian Steele 2 Dr. Christoph Hamelmann 3 Tedla Mezemir Dante 4
More informationGuidelines for application for Registration of Medicinal Products 2006(DRA)
Contact details: Drug Regulatory Authority, Thimphu Bhutan Telephone # 00975-2-334271, Fax: 00975-2-335803 Email : dra@health.gov.bt URL : www.health.gov.bt/dra.php Page 1 of 10 The guidelines outlined
More informationG/TBT/N/MYS/8 Proposal to enforce the Control of Drugs and Cosmetics Regulations 1984 on veterinary medicinal products.
G/TBT/N/MYS/8 Proposal to enforce the Control of Drugs and Cosmetics Regulations 1984 on veterinary medicinal products. The Health Minister of Malaysia, as conferred by subregulation 1(2) of the Control
More informationSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
More informationINVESTIGATIONAL PRODUCT ACCOUNTABILITY, STORAGE, DISPENSING, TRANSPORT AND RETURN
Policy/ Procedure # INVESTIGATIONAL PRODUCT ACCOUNTABILITY, STORAGE, DISPENSING, TRANSPORT AND RETURN 21 Effective Date June 2018 Category Global Last Review/Revision March 2017 Sub-Category Research Standards
More informationValidation Needs for Sterilization by Aseptic Filtration
Validation Needs for Sterilization by Aseptic Filtration DCVMN Workshop, Hyderabad, 4-8 April 2016 Ramesh Raju Associate Director - Provantage Validation Services Overview Key Regulatory and Industry guidelines
More informationCompounding Questions and Answers
Compounding Questions and Answers JANUARY 10, 2011 1. Question: What is a reliable supplier? Answer: Some examples of reliable suppliers are FDA licensed manufacturers, CA Department of Public Health Food
More informationDocumentation requirements for an initial consultation
Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationEssential Requirements Straumann Custom-made Dental Restorative Devices According to 93/42/EEC annex I as amended by 2007/47/EC
Straumann's CAD (Computer Aided Design) software CARES Visual has built-in parameter checks to assure that a dental restorative device basically meets the generally applicable requirements. However, Institut
More informationCode of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products
Code of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products March 2014 Table of Content INTRODUCTION 3 Section 1: GENERAL RESPONSIBILITIES OF HOLDER
More informationThe following scenario illustrates the supply, receipting and movement of ANODE packs. Allocation and shipment of IMP
Guidance Sheet 11 IMP Management and Stock Control Participants in the ANODE Trial will receive an intravenous (IV) dose of either co-amoxiclav or an unmatched inactive placebo (0.9% saline). This is an
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationStandard Operating Procedures (SOP) for Donations of 3MDG funded supplies
Standard Operating Procedures (SOP) for Donations of 3MDG funded supplies Version 3.3 January 2017 1. CONTENTS 1. CONTENTS... 2 2. INTRODUCTION... 3 3. HOW TO AVOID EXPIRY... 4 4. UNDER WHICH CONDITIONS
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: MANUFACTURE OF THE FINISHED DOSAGE FORM
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/CVMP/126/95 FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: MANUFACTURE OF THE
More informationClinical trials from CRA s point of view
Clinical trials from CRA s point of view Dr Jacek S Gregorczyk MPharmS, PhD Clinical Research Associate (CRA) at MDS Pharma Services UK office - a global CRO REGULATION of CLINICAL TRIALS World Medical
More informationPREP Workshop # 20: Investigational Drug Accountability. Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS
PREP Workshop # 20: Investigational Drug Accountability Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS CME Disclosure Statement The North Shore LIJ Health System adheres
More informationInvestigational Medicinal Product (IMP) Management Standard Operating Procedure
Reference Number: UHB 040 Version Number: 3 Date of Next Review: 26 Apr 2019 Previous Trust/LHB Reference Number: T 363 Standard Operating Procedure Introduction and Aim This procedure is written to support
More informationPharmaceutical product means a restricted drug under the Health (Drugs and Poisons) Regulation 1996.
Waste Management This information sheet provides clarification on the various treatment and disposal mechanisms available for managing clinical or related wastes as required under the Environmental Protection
More information10/17/2016. Learning Objectives. What is Drug Accountability. Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP
PREPARATION FOR DRUG MANAGEMENT AND ACCOUNTABILITY IN A CTN CLINICAL TRIAL Presented by Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced
More informationPatricia Novo, MPA, MPH Beth Jeffries, BS, CCRP
PREPARATION FOR DRUG MANAGEMENT AND ACCOUNTABILITY IN A CTN CLINICAL TRIAL Presented by Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced
More informationUnit 208 Assist with the manufacture and assembly of medicinal products
Element 1 Element 2 Assist with the preparation and packaging Assist with the completion of the manufacturing and assembly process 341 342 Element 1 Element 2 Assist with the preparation and packaging
More informationThe GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G
The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G (1) INTRODUCTION The following guideline defines the stability data package for a drug
More informationDEVELOPMENT PHARMACEUTICS AND PROCESS VALIDATION
DEVELOPMENT PHARMACEUTICS AND PROCESS VALIDATION Guideline Title Development Pharmaceutics and Process Validation Legislative basis Directive 75/318/EEC as amended Date of first adoption April 1988 Date
More informationClinical Trial Unit, Hospital Pharmacy Central Denmark Region
Clinical Trial Unit, Hospital Pharmacy Central Denmark Region Letter of Introduction The aim of this Letter of Introduction is to clarify general guidelines for working with the Hospital Pharmacy Central
More informationSupply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017
Supply of aseptically - prepared doses of IMPs across legal boundaries Edition 1 December 2017 Endorsed and supported by: NHS Pharmaceutical Quality Assurance Committee 2017 with National Pharmacy Clinical
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More information1. CHEMICAL PRODUCT & COMPANY IDENTIFICATION Page: 1. Effective Date: 09/07/99 Date Printed: 06/16/04 MSD:
MATERIAL SAFETY DATA SHEET 1. CHEMICAL PRODUCT & COMPANY IDENTIFICATION Page: 1 24-Hour Emergency Phone Number: 989-636-4400 The Dow Chemical Company, Midland, MI 48674 Customer Information Center: 800-258-2436
More information1. CHEMICAL PRODUCT & COMPANY IDENTIFICATION Page: 1. Effective Date: 09/07/99 Date Printed: 06/16/04 MSD:
MATERIAL SAFETY DATA SHEET 1. CHEMICAL PRODUCT & COMPANY IDENTIFICATION Page: 1 24-Hour Emergency Phone Number: 989-636-4400 The Dow Chemical Company, Midland, MI 48674 Customer Information Center: 800-258-2436
More informationOur vision APL
Our vision We want be the most attractive partner and workplace for development and manufacturing of extemporaneous drug formulations and pharmaceuticals. APL 2018 2 Our task Our task is to develop and
More informationto The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government No. 29.
STATUTORY INSTRUMENTS SUPPLEMENT No. 8 28th March, 2014 STATUTORY INSTRUMENTS SUPPLEMENT to The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government.
More informationGuidance for Industry
Guidance for Industry Submission of Abbreviated Reports and Synopses in Support of Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationEuropean Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells)
European Academy of Hospital Pharmacy Biotechnology Educational Summit Clinical trials David Gerrett (Acknowledgment Mark Howells) Objectives Have an appreciation and overview of clinical trials Understand
More informationGood practices in quality control in pharmaceutical industry - Overview of regulatory guidelines
Review Article Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT Good practices in quality control (QC) department
More informationDossier for marketing authorization in the European Union
Dossier for marketing in the European Union Maida Todi} Institute of Pharmacology, Clinical Pharmacology and Toxicology "Pavel Stern", Faculty of Medicine, University of Sarajevo, Abstract Extensive and
More informationInvestigator s Responsibility
Investigator s Responsibility Introduction Investigator s Qualifications Clinical Trial Agreement Adequate Resources Medical Care of Trial Subjects Communication with IRB/IEC Study Initiation Patient Recruitment
More informationDocument Number: SOP IV Original SOP: March 2010 Revision Number: mjb SOP IV: Transport to Satellite Pharmacies Effective Date: April 2013
S.O.P. IV TRANSPORT of Study Medications to Satellite Pharmacies I. PURPOSE A. To clarify the responsibilities and procedures of the Investigational Pharmacy in the transportation of study medications
More informationGUIDELINE FOR THE STABILITY TESTING
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 GUIDELINE FOR THE STABILITY TESTING OF NON-PRESCRIPTION (OTC)
More informationConsultation by a notified body on an ancillary medicinal substance integrated in a medical device
Consultation by a notified body on an ancillary medicinal substance integrated in a medical device Documentation requirements for an initial consultation Language : French or English Because of the wide
More informationEarly Development Best Practices for Stability- Regulatory Perspective
Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment
More informationCVM Guidelines and Guidance Documents
CVM Guidelines and Guidance Documents No. 85 (VICH GL9) Good Clinical Practice U.S. Department of Health and Human Services Food and Drug Administration Center of Veterinary Medicine May 9, 2001 PDF version
More informationInvestigational New Drug Application
Investigational New Drug Application Regulatory Sponsor: Funding Sponsor: Study Product: Protocol Number: Name of the Sponsor-Investigator Department Name Address Phone Number Name of Primary Funding Institution
More informationCompleting. By the end of this chapter, you will be able to: Introduction. Chapter 16
Chapter 16 Completing Product Processing By the end of this chapter, you will be able to: l Explain the term cold chain l Describe the type of fridge used for correct storage of refrigerated products l
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More information9. EEA Qualified Pharmacy Technician Assessment Framework
9. EEA Qualified Pharmacy Technician Assessment Framework Subject Description 1 Chemistry to include: The structure and classification of inorganic chemicals, nuclear and electronic structure of atoms,
More informationUSP800: A quick summary and disposal. Brenda Denson, Pharm.D.
USP800: A quick summary and disposal Brenda Denson, Pharm.D. Objectives Review current USP800 guidelines on destruction of hazardous medications. Illustrate how a local pharmacy demonstrates compliance
More informationESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL
Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage
More informationVaccine Prequalification Dossier
Vaccine Prequalification Dossier Introduction The current process for prequalification of vaccines states that once a product is eligible for prequalification evaluation the manufacturer must submit a
More informationGMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides
FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics
More informationGUIDELINES FOR CONDUCTING CLINICAL TRIALS.
GUIDELINES FOR CONDUCTING CLINICAL TRIALS. FOREWORD The purpose of Drug Registration is to ensure that a pharmaceutical product has been adequately tested and evaluated for safety, efficacy and quality,
More informationAPPLICATION FOR MARKETING AUTHORIZATION OF A PHARMACEUTICAL PRODUCT FOR HUMAN USE IN UGANDA
National Drug Authority Plot No. 46-48 Lumumba Avenue, P.O. Box 23096, Kampala, Uganda. email: ndaug@nda.or.ug; website: www.nda.or.ug Doc. No.: DAR/FOM/170 Revision No.: 1 Effective Date: 21 June 2016
More informationSPONSOR INVESTIGATIONAL MEDICINAL PRODUCT (IMP) MANAGEMENT
SPONSOR INVESTIGATIONAL MEDICINAL PRODUCT (IMP) MANAGEMENT DOCUMENT NO.: GS010 v1.0 AUTHOR: Vikki Young ISSUE DATE: 28 MAY 2018 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research &
More informationPHARMACY, MEDICINES & POISONS BOARD
PHARMACY, MEDICINES & POISONS BOARD PHARMACY GUIDELINES FOR INVESTIGATIONAL DRUGS A. Purpose These guidelines are principally derived and adapted from guidelines from various sources within the SADC region.
More informationGUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA
GUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA Issued by the Registrar: Act No. 36 of 1947, Private Bag X343, Pretoria 0001 Republic of South Africa Tel. (**27
More informationGuidance for Industry
Guidance for Industry 85 GOOD CLINICAL PRACTICE VICH GL9 FINAL GUIDANCE (This document was revised on June 8, 2011 to update the contact information, add the Table of Contents, update hyperlinks, and minor
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationSAFETY DATA SHEET. March 1, 2017
Tex-Trude, LP urges each customer or recipient of this Safety Data Sheet to study it carefully to become aware of and understand the hazards (or not) that are associated with the product This (SDS) is
More informationICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More information10.0 DISPOSAL OF FARM WASTE
DISPOSAL OF FARM WASTE 10.1 Disposal of Dead Animals 10.1.1 Managing dead animal disposal 10.2 Disposal of Veterinary Waste 10.3 Pesticides 10.2.1 Sharps 10.2.2 Medicine disposal 10.3.1 Pesticide disposal
More informationDate: 21 st May 2014 Version: 5 Page 1 of 11. Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May 2014
Date: 21 st May 2014 Version: 5 Page 1 of 11 STANDARD OPERATING PROCEDURE FOR MONITORING CLINICAL TRIALS (NWORTH 3.07) Approvals Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May
More informationSession 7 Clinical Trial Assessment Bioequivalence Studies
L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationNIMPs (v IMPs): Definitions and Practical Approaches
NIMPs (v IMPs): Definitions and Practical Approaches Esther Sadler-Williams Global Director Strategic Development and Innovation 18 th November 2015 2015 Catalent Pharma Solutions. All rights reserved
More informationTITLE: Research Pharmacy Standard Policy SOP #: INV-100 Page: 1 of 5 Effective Date: 8/31/17
SOP #: INV-100 Page: 1 of 5 1. POLICY STATEMENT: DF/HCC research pharmacies follow a standard set of policy requirements for clinical trials. 2. BACKGROUND: None 3. RESPONSIBLE PERSONNEL: 3.1. Research
More informationSupersedes Division Name Revision No. 0 Export Division Page No. 1 of 9
Page No. 1 of 9 Control Status 1.0 Purpose To lay down a procedure for conducting GMP inspection and report writing for issue of Written Confirmation for for medicinal products for human. 2.0 Scope This
More informationGUIDELINE FOR REGISTRATION OF MEDICINES
MEDICINES CONTROL AGENCY 54 Kairaba Avenue, Pipeline, The Gambia. Tel.no. +220 4380632 GUIDELINE FOR REGISTRATION OF MEDICINES Document number: MCA-GL-102 Date of issue: 12 February 2018 Version: 2.0 Date
More information